Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naronapride - Renexxion

Next Previous
Drug Profile

Naronapride - Renexxion

Alternative Names: ATI-7505

Latest Information Update: 16 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARYx Therapeutics
  • Developer ARYx Therapeutics; Dr Falk Pharma; Renexxion
  • Class Anti-inflammatories; Benzamides; Gastrokinetics; Laxatives; Quinuclidines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Constipation; Gastro-oesophageal reflux; Gastroparesis; Non-ulcer dyspepsia
  • Discontinued Erosive oesophagitis

Most Recent Events

  • 08 Jan 2026 Renexxion has patent protection for Naronapride Trihydrate Formulation, dosage forms and methods of use for treating a range of GI disorders
  • 09 Sep 2025 Dr Falk Pharma initiates a phase I pharmacokinetic trial in Healthy volunteers in Portugal (CTIS2024-520215-40-00)
  • 27 May 2025 Dr Falk Pharma completes enrolment in the phase IIb MOVE-IT trial for Gastroparesis (In the elderly, In adults) in Germany, Belgium, Poland, France, Latvia the Netherlands, the US and Italy (PO) (NCT05621811)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top